Medgenics gets Orphan Drug Designation from FDA for Biopump technology
Medgenics (LON:MEDG NYSE:MDGN) said it has received Orphan Drug Designation (ODD) from US regulator Food and Drug Administration for the INFRADURE Biopump to treat Hepatitis D.The statement was...
View ArticleMedgenics appoints new chairman
Medgenics (LON:MEDG, NYSE:MDGN) has appointed the former chief executive of global biopharmaceutical, Celgene Corporation (NASDAQ: CELG), as chairman of its board. Dr Sol Barer will replace Dr Eugene...
View ArticleMedgenics demonstrates Biopump technology potential as it enters inflection...
Medgenics (LON:MEDG, LON:MEDU NYSE:MDGN) chief executive Dr. Andrew Pearlman says its Biopump technology has the potential to “start a whole new pharmaceutical industry”. “Our technology has promise to...
View ArticleMedgenics starts phase IIa trials for anaemia Biopump treatment
Medgenics (LON:MEDG) has enrolled the first subjects to test its Biopump for treating anaemia in patients with kidney disease and on dialysis, at its research centre in Israel. Medgenics said the...
View ArticleMedgenics reports on significant period of change as advances trials
Medgenics’ (LON:MEDG, NYSE:MDGN) quarterly results reflected a period of significant progress for the medical technology group. Research expenditure and general administrative costs rose as the...
View ArticleMedgenics appoints Dr Marvin Garovoy as chief medical officer
Medgenics (LON:MEDG, NYSE:MDGN) has appointed Dr Marvin Garovoy as chief medical officer – a role he has held in a temporary capacity since January. Garovoy has been involved in clinical development...
View ArticleMedgenics receives approval for hepatitis trial plans
AIM quoted Medgenics (LON:MEDG, NYSE:MDGN) is now preparing for the first 'in human' trial for the use of its INFRADURE technology in the treatment of hepatitis C. This comes as Israel's Ministry of...
View ArticleMedgenics to present EPODURE at Kidney Week 2012
Medgenics (LON:MEDG, NYSE:MDGN) has revealed it will present its EPODURE Biopump in a poster session at the American Society of Nephrology's Kidney Week 2012. Its poster titled “Novel Sustained...
View ArticleMedgenics to present EPODURE at Kidney Week 2012
Medgenics (LON:MEDG, NYSE:MDGN) has revealed it will present its EPODURE Biopump in a poster session at the American Society of Nephrology's Kidney Week 2012. Its poster titled “Novel Sustained...
View ArticleMedgenics: Phase II EPODURE procedure "went well”
Medgenics (LON:MEDG) this morning gave an early, but very encouraging hint as to the progress of its potentially revolutionary EPODURE system for treating anaemia in patients on kidney dialysis....
View ArticleMedgenics: Phase II EPODURE procedure "went well”
Medgenics (LON:MEDG) this morning gave an early, but very encouraging hint as to the progress of its potentially revolutionary EPODURE system for treating anaemia in patients on kidney dialysis....
View ArticleMedgenics reflects on a quarter of significant progress
Third quarter results from Medgenics (LON:MEDG, AMEX:MDGN) reflect a period of huge progress in which its two main treatments have passed key milestones. Its scientists are developing the BIOPUMP...
View ArticleMedgenics shares rise on US patent news
Biopump developer Medgenics (LON:MEDG) shares were lifted in London after it won a patent from the US authorities to protect the technology associated with the device. The US Patent and Trademark...
View ArticleMedgenics shares rise on US patent news
Biopump developer Medgenics' (LON:MEDG) shares were lifted after it won a patent from the US authorities to protect the technology associated with the device. The US Patent and Trademark Office (USPTO)...
View ArticleMedgenics' INFRADURE enthuses hepatitis specialists
Experts at a medical conference in Boston have agreed that the INFRADURE treatment developed by Medgenics (LON:MEDG) has the potential to eliminate the hepatitis B virus. INFRADURE is being developed...
View ArticleMedgenics' key patent claims allowed in Japan
Medgenics (LON:MEDU, NYSE:MDGN) has received what’s called a notice of allowance from Japan’s Patent and Trademark Office for Infradure, its slow release treatment for hepatitis B, C and D. Infradure...
View ArticleMedgenics kicks off trial of hepatitis C treatment
Medgenics (LON:MEDG, LON:MEDU, NYSE:MDGN), one of the best performing stocks of last year, has kicked off the clinical trial of its INFRADURE Biopump treatment of hepatitis C.The first patient has...
View ArticleMedgenics recruits new director
Biopump developer Medgenics (LON:MEDG) has appointed Joseph Grano Jr as a director to replace Gary Brukardt, who died in 2012. Grano is chairman and chief executive (CEO) of Centurion Holdings, a...
View ArticleMedgenics lifted by US patent decision
Medgenics (LON:MEDU,AMEX:MDGN), inventor of the Biopump device for the sustained production and delivery of medicines to treat chronic diseases such as anaemia and hepatitis C, said the US Patent...
View ArticleMedgenics reports "encouraging" data from Epodure Biopump trial
Medgenics (LON:MEDG) unveiled what it described as encouraging early data from the phase IIa clinical trial of its potentially revolutionary EPODURE Biopump device. It is currently being used to...
View Article
